Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

Gilead Sciences, Inc.’s GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 2025) due to ongoing competitive ...

As artificial intelligence (AI) tools continue to proliferate, they are becoming a go-to search tool for patients, providers, ...

I recently found out that my aunt was diagnosed with cancer and may need chemotherapy. When I think of chemotherapy, I ...

“The full end-to-end clinical pathway – from blood draw at a collection site through to result delivery to the ordering clinician – has now been successfully completed in a routine clinical setting,” ...

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in the coming years.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor sec ...

Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.